Targeted Oncology Staff

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen Oh, MD, discussed treatment options for steroid-refractory high-risk primary myelofibrosis based on the patient's platelet count.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed the results of the BOSTON trial of selinexor in patients with relapsed/refractory multiple myeloma.

Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed the available therapy options for a patient with advanced hepatocellular carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hatim Husain, MD, discussed data on targeted adjuvant therapy for non–small cell lung cancer.

Sara Hurvitz, MD, discusses recent updates for selective estrogen receptor degraders in the treatment of patients with metastatic breast cancer and how it has impacted clinical decisions.

In separate live, virtual events, Ulka N. Vaishampayan, MBBS, and David A. Braun, MD, PhD, discussed options for a patient with favorable-risk clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses how targeting patients with relapsed/refractory multiple myeloma with B-cell maturation antigens like teclistamab is changing the treatment landscape.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.

During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Geynisman, MD, discussed with participants the choice of hormonal therapy for metastatic prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Finn, MD, discussed how treatment options for patients with hepatocellular carcinoma have advanced in recent years.

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their choice of combination therapy after disease relapse of multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bhavana Pothuri, MD, MS, discussed with participants their experiences managing adverse events of immunotherapy for advanced endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the trials supporting the use of mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed 3 recommended agents for treatment of chronic graft-vs-host disease. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Marcia S. Brose, MD, PhD, discussed the case of a patient with advanced thyroid cancer who was previously treated with radioactive iodine and has an NTRK fusion alteration.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sikander Ailawadhi, MD, discussed with participants the choice of regimen for a patient with transplant-eligible newly diagnosed multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.

Aditya Bardia, MD, MPH, discussed potential second-line therapies for patients with metastatic triple-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Evan Y. Yu, MD, discussed with participants role of prostate-specific membrane antigen in metastatic castration-resistant prostate cancer.

At a live virtual event, Andrew Kuykendall, MD, discussed the rationale and data for the use of pacritinib in patients with high-risk primary myelofibrosis.

Benjamin Philip Levy, MD, discussed systemic therapies for patients with ALK-rearranged metastatic non–small cell lung cancer and data from recent trials in this space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer. This is the third of 3 articles based on this event.

From the new approval for sacituzumab govitecan for a breast cancer subgroup to dostarlimab for dMMR advanced endometrial, February 2023 was an important month of FDA activity.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.